Oral Therapeutic Agents with Highly Clustered Globotriose for Treatment of Shiga Toxigenic Escherichia coli Infections

Journal of Infectious Diseases

Volumn 189, Issue 3, 2004, Pages 360-368

  Watanabe, Miho ^a,b   Matsuoka, Koji ^c   Kita, Eiji ^e   Igai, Katsura ^a,d   Higashi, Nobutaka ^e   Miyagawa, Atsushi ^c   Watanabe, Toshiyuki ^c   Yanoshita, Ryohei ^b   Samejima, Yuji ^b   Terunuma, Daiyo ^c   Natori, Yasuhiro ^a   Nishikawa, Kiyotaka ^a,d  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b HOSHI UNIVERSITY   (Japan)

^c SAITAMA UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE; GLOBOTRIAOSYLCERAMIDE; POLYMER; PROTEIN SUBUNIT; SHIGA TOXIN; TRISACCHARIDE;

ADSORPTION; ANIMAL CELL; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BINDING AFFINITY; BINDING ASSAY; BLOOD LEVEL; BRAIN INJURY; CELL PROTECTION; CIRCULATION; CYTOTOXICITY; DENSITY; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRULENCE;

ACRYLAMIDE; ANIMALS; BRAIN CHEMISTRY; CARBOHYDRATE SEQUENCE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FEMALE; HEMOLYTIC-UREMIC SYNDROME; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; POLYMERS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; SHIGA TOXINS; SHIGA-LIKE TOXIN I; SHIGA-LIKE TOXIN II; TRIHEXOSYLCERAMIDES; TRISACCHARIDES;

EID: 10744227433     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381124     Document Type: Article

References (26)

1. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of hemolytic uremic syndrome associated with fecal cytotoxin and cytotoxin-producing Escherichia coli. Lancet 1983; 1:619-20.
2. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308:681-5.
3. O'Brien AD, Holmes RK. Shiga and Shiga-like toxins. Microbiol Rev 1987; 51:206-20.
4. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-79.
5. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 1989; 160:994-8.
6. Tesh VL, Burris JA, Owens JW, et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 1993; 61:3392-402.
7. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coll. J Infect Dis 1985; 151:775-82.
8. Melton-Celsa AR, O'Brien AD. Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals. In: Kaper JB, O'Brien AD, eds. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington, DC: American Society for Microbiology Press, 1998:121-8.
9. Armstrong GD, Fodor E, Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J Infect Dis 1991; 164:1160-7.
10. Kitov PI, Sadowska JM, Mulvey G, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000; 403:669-72.
11. Dohi H, Nishida Y, Mizuno M, et al. Synthesis of an artificial glycoconjugate polymer carrying Pk-antigenic trisaccharide and its potent neutralization activity against Shiga-like toxin. Bioorg Med Chem 1999; 7:2053-62.
12. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6:265-70.
13. Nishikawa K, Matsuoka K, Kita E, et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci USA 2002; 99:7669-74.
14. Paton JC, Rogers TJ, Morona R, Paton AW. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli. Infect Immun 2001; 69:1389-93.
15. Matsuoka K, Terabatake M, Esumi Y, Terunuma D, Kuzuhara H. Synthetic assembly of trisaccharide moieties of globotriaosyl ceramide using carbosilane dendrimers as cores: a new type of functional glycomaterial. Tetrahedron Lett 1999; 40:7839-42.
16. Matsuoka K, Nishimura S-I. Synthetic glycoconjugates. 5. Polymeric sugar ligands available for determining the binding specificity of lectins. Macromolecules 1995; 28:2961-8.
17. Noda M, Yutsudo T, Nakabayashi N, Hirayama T, Takeda Y. Purification and some properties of Shiga-like toxin from Escherichia coli O157:H7 that is immunologically identical to Shiga toxin. Microb Pathog 1987; 2:339-49.
18. Kurazono H, Sasakawa C, Yoshikawa M, Takeda Y. Cloning of a Vero toxin (VT1, Shiga-like toxin I) gene from a VT1-converting phage isolated from Escherichia coli O157:H7. FEMS Microbiol Lett 1987; 44:23-6.
19. Nishikawa K, Arai H, Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem 1990; 265:5226-31.
20. Plant AL, Brigham-Burke M, Petrella EC, O'Shannessy DJ. Phospholipid/alkanethiol bilayers for cell-surface receptor studies by surface plasmon resonance. Anal Biochem 1995; 226:342-8.
21. Kurioka T, Yunou Y, Kita E. Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice. Infect Immun 1998; 66:1726-34.
22. Dohi H, Nishida Y, Takeda T, Kobayashi K. Convenient use of non-malodorous thioglycosyl donors for the assembly of multivalent globo- and isoglobosyl trisaccharides. Carbohydr Res 2002; 337:983-9.
23. Lingwood CA, Mylvaganam M, Arab S, et al. Shiga toxin (verotoxin) binding to its receptor glycolipid. In: Kaper JB, O'Brien AD, eds. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington, DC: American Society for Microbiology Press, 1998:129-39.
24. Miura Y, Sasao Y, Dohi H, Nishida Y, Kobayashi K. Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with shiga toxins. Anal Biochem 2002; 310:27-35.
25. Takeda T, Yoshino K, Adachi E, Sato Y, Yamagata K. In vivo assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2. Microbiol Immunol 1999; 43:331-7.
26. Rogers JE, Armstrong G, O'Brien AD. Therapeutic value of Stx-specific antibodies or synsorb in streptomycin (STR)-treated mice orally infected with Shiga toxin-producing Escherichia coli (STEC) [abstract V149/VII]. In: Program and abstracts of the 3rd International Symposium and Workshop on Shiga Toxin (Verotoxin)-Producing Escherichia coli Infections (Baltimore). Melville, NY: Lois Joy Galler Foundation for Hemolytic Uremic Syndrome, 1997:114.